Wysa vs Abridge

Abridge has a disclosed valuation of $5.3B, while Wysa's valuation is not publicly available, making a direct size comparison difficult. Abridge employs 120 people.

Abridge has raised more in total funding at $800M, compared to Wysa's $30M — a gap of $770M. Combined, the two companies have completed 7 known funding rounds.

Abridge leads with an Awaira Score of 76/100, while Wysa sits at 63/100. That 13-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Wysa was founded by Jo Aggarwal in 2015. Abridge was founded by Shiv Rao in 2018. Visit each company's profile on Awaira for a full founder biography.

Wysa: Wysa is an AI mental health platform that provides evidence-based cognitive behavioral therapy techniques through a conversational AI chatbot, offering anonymous, stigma-free mental health support accessible via smartphone at any hour. The platform uses clinically validated CBT, DBT, and mindfulness exercises delivered conversationally, and provides a step-up pathway to licensed human therapists for users requiring more intensive support.\n\nThe company raised approximately $30M in Series B funding and has deployed its platform to over five million users globally, including through enterprise employee wellness programs, NHS partnerships in the UK, and healthcare system integrations in the United States and India. Wysa has published peer-reviewed clinical evidence demonstrating statistically significant improvements in depression and anxiety scores.\n\nMental health care access is a global crisis with a severe therapist shortage that AI can meaningfully address at the first-line support level. Wysa's combination of clinical validation, enterprise and payer relationships, and scalable AI delivery model positions it as one of the more credible players in the crowded digital mental health space. Abridge: Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers. The company's core product uses artificial intelligence to automatically generate clinical notes from patient-physician conversations, addressing the administrative burden that consumes significant physician time. Abridge's technology uses natural language processing and machine learning to transcribe, analyze, and summarize medical interactions, converting spoken dialogue into structured clinical documentation that integrates with existing electronic health record systems. The platform targets healthcare systems, hospitals, and outpatient practices seeking to reduce documentation workload and improve clinical efficiency. The company has secured $150M in total funding and maintains a valuation of $800M as of its Series B stage, reflecting investor confidence in the clinical AI documentation market. Abridge competes alongside other healthcare AI vendors addressing documentation automation, including companies focused on ambient clinical intelligence and voice-to-note solutions. The healthcare industry's ongoing digitization and physician burnout trends have created substantial demand for documentation automation tools. The company's growth trajectory reflects expanding adoption within healthcare systems seeking to improve provider productivity and patient interaction quality. Abridge's position in the AI health landscape centers on practical workflow optimization rather than diagnostic or treatment algorithms, targeting a specific high-value pain point in clinical operations. Abridge transforms clinical conversations into automated documentation, directly addressing physician administrative burden through ambient voice intelligence.

Wysa got there first, launching in 2015 — that's 3 years of extra runway. Abridge didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Wysa has about 50-200 employees; Abridge has about 120. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Wysa and Abridge compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.